Our Mission
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
News Releases
Year
News Releases
- Aug. 8, 2025 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Aug. 7, 2025 - Puma Biotechnology Reports Second Quarter Financial Results Read
- July 24, 2025 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results Read
- July 2, 2025 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- June 4, 2025 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- May 8, 2025 - Puma Biotechnology Reports First Quarter Financial Results Read
- May 6, 2025 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- April 28, 2025 - Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 Read
- April 24, 2025 - Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results Read
- April 2, 2025 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Mar. 26, 2025 - Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025 Read
- Mar. 5, 2025 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Feb. 27, 2025 - Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results Read
- Feb. 26, 2025 - Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference Read
- Feb. 13, 2025 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results Read
- Feb. 5, 2025 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Jan. 3, 2025 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read